Evil from the mouth: oral version of Shumeile exposed security risks

Drug Source Analysis Although today's drug King Shumeile is facing the threat of K medicine and patent expiration is about to leave office, but this product and the entire family of TNF inhibitors is one of the most successful drugs in the history of new drugs.
is that this path is associated with many autoimmune diseases, and Shumeile has more than a dozen adaptations, large and small, that have become classic cases of platform drugs.
But such an important path is also involved in many normal physiological processes, so the risks and benefits depend more on the severity of the disease, other competitive therapies, drug interventions, drug selectivity and many other factors.
was listed in 2002, when common chronic diseases were the direction of the pharmaceutical owners.
at that time, the drug king once a day oral lipid-lowering drug Lipto is the highest ideal of large and small pharmaceutical technology, subtly affecting the development strategy of new drugs.
quickly acquired several labels for large autoimmune diseases, and sales have shown the potential of heavy drugs since the second year.
But one obvious drawback of this antibody drug is the need for injections, especially for arthritis, a particular disease, many patients because of joint mobility inconvenience self-injection is very difficult, and some patients are born with needles.
at that time, oral drugs such as the pressure of the day many manufacturers are doing their best to find oral version of the shumeile.
TNF binds to the subject and requires JAK family kinases in the cell to transmit this information, so JAK family inhibitors, including now the new high-priced TYK2 inhibitors of psoriasis, are the first target.
but at the time kinase inhibitors were still in their infancy and their use was completely limited to the tumor field.
Pfizer was the first to list Xeljanz, an off-tumor kinase inhibitor, a compound that was much better than other kinase inhibitors at the time, both selective and chemical in nature, greatly enhancing the credibility of kinase inhibitors.
that although this compound is selective in kinase inhibitors, it is still a JAK1/JAK3 double inhibitor.
article published by Pfizer at the time suggested that the dual-target activity may have been the cause of better-than-expected efficacy, but now looking back may have been involved in side effects.
not just Xeljanz, but in recent years the entire JAK family of inhibitors has been plagued by side effects, mostly with black-box warnings, and experts predict today's results will make the FDA more cautious about such drugs.
, a widely expressed, politically active wild target, may play an important role in the development of multiple diseases and may therefore produce platform drugs, the other side of the coin may also have more side effects.
even if drug selectivity is not taken into account, a single protein dysfunction can cause a wide range of symptoms of so-called syndrome, drug intervention may produce a variety of side effects.
of course the JAK family also experiences useful side effects such as promoting hair regeneration.
results are also reminiscent of the experience of another type of anti-inflammatory drug, COX2 inhibitors.
COX2 was also a promising arthritis drug, but it was later found to increase cardiovascular events and lead to The Withdrawal of Wanlo.
the human body in the evolution process to balance a variety of losses, anti-cancer drugs often ask why the immune system can not work and try to prevent the occurrence of tumors.
in fact autoimmune diseases may be to avoid the cost to the body of cardiovascular, tumor and other diseases that have a greater impact on species continuation before transmission.
it's a little hard for drug chemists to interfere with this elaborate and complex mechanism with a crude dose with limited selectivity and close to KO activity.